Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's disease.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology - 1 Apr 2025

Raza Amir, Raina Jeevika, Sahu Sanjeev Kumar, Wadhwa Pankaj

Abstract excerpt

This comprehensive review navigates the landscape of genetic mutations in kinases, offering a thorough examination of both marketed inhibitors and unexplored targets in the context of Parkinson's Disease (PD). Although existing treatments for PD primarily center on symptom management, progress in comprehending the molecular foundations of the disease has opened avenues for targeted therapeutic approaches. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Plant Gene Expression Analysis

Source

Identifiers

PMID: 39760821
DOI: 10.1007/s10072-024-07970-2

Genes

GAK
PINK1
PRKRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic mutations in kinases: a comprehensive review on marketed inhibitors and unexplored targets in Parkinson's diseasePMID 39760821Read ↗

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased riskSemantic proximity Read ↗

Characterizing the role of the dark kinome in neurodegenerative disease – A mini reviewSemantic proximity Read ↗

Protein Kinases and Parkinson’s DiseaseSemantic proximity Read ↗

Leucine Rich Repeat Kinase 2: beyond Parkinson's and beyond kinase inhibitors.Semantic proximity Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.Semantic proximity Read ↗

DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspectiveSemantic proximity Read ↗

Exploring Missense Mutations in Tyrosine Kinases Implicated with Neurodegeneration.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.Semantic proximity Read ↗

Recent Developments in LRRK2-Targeted Therapy for Parkinson’s DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.